Dendreon to offer end-to-end cell therapy manufacturing

By The Science Advisory Board staff writers

June 16, 2021 -- California-based Dendreon Pharmaceuticals announced that it will offer end-to-end manufacturing for complex cell therapies.

The company is one of only four firms that manufacture cell therapies for commercial use in the U.S. In early 2021, Dendreon started to dedicate capacity for later-stage partner programs within its current infrastructure.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.